Relay Therapeutics Q1 net loss $81.4M; cash $749.6M, Genentech milestone boosts revenue

Relay Therapeutics, Inc.

2024-Q1 EPS reported -$0.62 revenue$10,007,000

Net loss $81.4M ($0.62/share) vs $94.2M ($0.78/share) in Q1 2023; loss narrowed.
Revenue $10.0M vs $0.2M YoY, driven by $10M milestone from Genentech collaboration.
Cash and investments $749.6M, expected to fund operations into H2 2026.
R&D expenses $82.4M, relatively flat vs $82.8M year ago.
RLY-2608 doublet and triplet trials enrolling; lirafugratinib data and regulatory update expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported first quarter 2024 results: revenue $10.0 million, net income $81.4 million, EPS $0.62.

Period: first quarter 2024
Revenue: $10.0 million
Net income: $81.4 million
EPS: $0.62
Result: reported results

Exact text from the filing

The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $10.0 million for the first quarter of 2024, as compared to $0.2 million for the first quarter of 2023. The increase was primarily due to a payment of $10.0 million in connection with a

View on SEC.gov

222 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.